How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Pricing group says weight-loss drugs becoming more cost-effective
By Deena Beasley (Reuters) -An influential drug pricing watchdog on Tuesday said popular GLP-1 weight-loss injections have become…
Ozempic, other weight-loss drug makers face lawsuits. Here’s what we know
Claim: Pharmaceutical companies behind weight loss and diabetes medication such as Ozempic are facing a lawsuit that could…
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
Ozempic® is the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes…
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH,…
Novo Nordisk’s obesity drug Wegovy cleared to treat live disease MASH
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators on Friday to treat an increasingly common liver…
Mom, 58, Used a ‘Miracle’ GLP to ‘Be Thin’ for Her Son’s Wedding. She Claims It Made Her So Sick She Almost Missed the Big Day
NEED TO KNOW Ali Eastburn, a 58-year-old mom from Nashville, was struggling with losing weight after menopause She…
Will you take Wegovy to lose weight?
Wegovy is now available in Singapore more than two years after it was approved by the Health Sciences…
GLP-1 drugs for addiction: Confidence grows in new treatment option
WERNERSVILLE, Pa. — To make sense of the reds and greens dancing across a computer monitor displaying a…
Major insurance changes are coming for weight loss drugs
Last week, Tara Eacobacci had an appointment with her doctor that was devoted exclusively to the topic of…